Skip to content
Sanjivani Paranteral logo

Sanjivani Paranteral

531569 BSE
Price unavailable

Sanjivani Paranteral (SANJIVIN) share price was ₹174.25 at the 28 Oct 2026 close; market capitalisation ₹214 Cr; P/E (TTM) 28.66; sector Healthcare. The share price fell 12.2% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 33.3% year on year to ₹23.84 Cr and net profit rose 43.9% year on year to ₹2.49 Cr (compared with Jun 2025). Promoters held 31.56% of Sanjivani Paranteral in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 41/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹174.25 −29.90 −14.65% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹214 Cr
P/E (TTM)
28.66
EBITDA
₹11.30 Cr
Return on Equity
13.17%
Debt to Equity
0.3
Book Value
₹39.28
EPS (TTM)
₹6.08
52W High
₹244.00
52W Low
₹126.00

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.5035.044,23,843 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,631.0087.412,55,673 Cr15.250.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,596.5072.161,74,836 Cr9.520.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,183.50107.881,17,977 Cr22.260.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.9026.281,17,795 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.8034.731,11,914 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.8032.841,10,741 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Sanjivani Paranteral (this company)
—28.66214 Cr4.440.30%13.17%16.30%76 Cr7 Cr
Median 8 companies₹1,766.5034.891,17,886 Cr4.760.47%13.48%17.12%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

41 Weak
Overall score

Data confidence 98/100

Category scores

Quality Poor 28
Returns, margins, earnings quality 22% weight
Valuation Poor 35
Cheap vs sector & own history 24% weight
Growth Weak 43
Sales & profit trajectory 9% weight
Financial Health Good 60
Solvency, leverage, coverage 9% weight
Momentum Good 66
Trend strength, vol-adjusted 12% weight
Ownership Weak 44
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Weaknesses

3
  • Promoter holding is low: 31.6%
  • Company might be capitalizing the interest cost
  • Debtor days have increased from 66.8 to 82.0 days.

Technical Indicators

Oscillators

Bearish

Bearish
3
Neutral
6
Bullish
0

Overall

Bullish

Bearish
5
Neutral
6
Bullish
8

Moving Averages

Bullish

Bearish
2
Neutral
0
Bullish
8

Growth Rate

Revenue Growth
-2.1% lower than 3Y

change over 1 year

Net Income Growth
-17.28% lower than 3Y

change over 1 year

Cash Flow Change
-101%

change over 1 year

EBITDA Margin Change
-0.49%

change over 1 year Operating margin 17.49% · Jun 2026

Quarterly Results

Particulars Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
14.96
12.86
16.44
18.13
17.35
18.18
17.89
15.5
22.06
13.21
23.84
Expenses
12.99
10.7
14.1
15.28
14.8
15.57
15.25
13.25
18.22
11.64
19.67
Operating Profit
1.97
2.16
2.34
2.85
2.55
2.61
2.64
2.25
3.84
1.57
4.17
OPM %
13.17%
16.8%
14.23%
15.72%
14.7%
14.36%
14.76%
14.52%
17.41%
11.88%
17.49%
Other Income
0.25
0.05
0.09
0.39
0.31
0.43
0.04
0.16
0.3
0.6
0.15
Interest
0.08
0.09
0.02
0.18
0.19
0.2
0.22
0.05
0.21
0.31
0.35
Depreciation
0.24
0.24
0.13
0.15
0.16
0.18
0.16
0.17
0.23
0.66
0.65
PBT
1.9
1.88
2.28
2.91
2.51
2.66
2.3
2.19
3.7
1.2
3.32
Tax %
13.16%
33.51%
24.56%
21.31%
24.3%
17.29%
24.78%
25.11%
24.86%
55%
25%
Net Profit
1.65
1.26
1.71
2.3
1.9
2.19
1.73
1.64
2.78
0.55
2.49
EPS (₹)
1.65
1.08
1.46
1.97
1.6
1.84
1.43
1.34
2.26
0.45
2.03
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2024Mar 2025Mar 2026TTM
Sales
54.41
70.1
68.67
74.61
Expenses
46.18
59.76
58.38
62.78
Operating Profit
8.23
10.34
10.29
11.83
OPM %
15.13%
14.75%
14.98%
15.86%
Other Income
0.52
1.22
0.97
1.21
Interest
0.25
0.59
0.65
0.92
Depreciation
0.93
0.62
1.22
1.71
PBT
7.57
10.35
9.39
10.41
Tax %
18.63%
21.84%
28.75%
—
Net Profit
6.17
8.09
6.69
7.46
EPS (₹)
5.28
6.81
5.45
6.08
Div. Payout %
0%
7.34%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2024Mar 2025Mar 2026
Equity Capital
11.68
11.88
12.28
Reserves
16.22
26.11
35.96
Borrowings
0.97
8.14
14.28
Other Liabilities
14.53
32.07
25.46
Total Liabilities
43.4
78.2
87.98
Fixed Assets
9.94
20.64
47.34
CWIP
0
19.11
1.15
Investments
0
0
0.73
Other Assets
33.46
38.45
38.76
Total Assets
43.4
78.2
87.98
Figures in ₹ Crores

Cash Flow

Particulars Mar 2024Mar 2025Mar 2026
Operating
-10.7
12.4
-0.11
Investing
-12.21
-21.91
-9.97
Financing
23.16
10.46
9.84
Net Cash Flow
0.24
0.94
-0.24
Free Cash Flow
-14
-17.95
-10.18
CFO/OP
-117
133
20
Figures in ₹ Crores

Ratios

Particulars Mar 2024Mar 2025Mar 2026
Debtor Days
31.53
86.85
82.01
Inventory Days
125
94.77
91.17
Days Payable
73.56
138
30.61
Cash Conversion Cycle
82.67
44.11
143
Working Capital Days
35.55
-0.1
45.98
ROCE %
—
28.46%
17.96%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sanjivani Paranteral insights

65 extracted metrics + investor summaries across FY10–FY27.

Shareholding Pattern

DIIs4.90%Public50.50%Others13.03%Promot.31.56%As ofSep 2026

Documents

Frequently Asked Questions about Sanjivani Paranteral

What does Sanjivani Paranteral Ltd do?
Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]
Where is Sanjivani Paranteral Ltd (SANJIVIN) listed?
Sanjivani Paranteral Ltd trades under code 531569 on the BSE.
Which sector does Sanjivani Paranteral Ltd belong to?
Sanjivani Paranteral Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd has a market capitalisation of ₹214.1 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd trades at a PE ratio of 28.66 as of 28 Oct 2026, on earnings per share of ₹6.08, against a book value of ₹39.28 per share.
What is the 52-week high and low of Sanjivani Paranteral Ltd?
Over the last 52 weeks Sanjivani Paranteral Ltd has traded between ₹126 and ₹244 as of 28 Oct 2026.
Does Sanjivani Paranteral Ltd pay dividends?
Sanjivani Paranteral Ltd has a dividend yield of 0.29%.
What is the Return on Equity (ROE) of Sanjivani Paranteral Ltd?
Sanjivani Paranteral Ltd reported a return on equity of 13.17%. Its debt-to-equity ratio is 0.30.

Company Information

Incorporated in 1994, Sanjivani Parenteral Ltd is a research-based and export-oriented pharmaceutical company[1]

Website sanjivani.co.in
Face Value ₹ 10
Shares Outstanding 1,22,86,941

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531569.md for Sanjivani Paranteral Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month